Form 4: Kura Oncology Director, Helen Collins, Acquires 26,000 Stock Options
SEC Form 4 Filing
Director Helen Collins reports acquisition of 26,000 stock options in Kura Oncology, Inc.
Summary
- Helen Louise Collins, a director of Kura Oncology, Inc., reported a transaction on June 5, 2024.
- Collins acquired 26,000 options to purchase common stock at a price of $21.79.
- These options vest in full on the one-year anniversary of the grant date and expire on June 4, 2034.
- Following the transaction, Collins directly owns 26,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of stock option acquisition by a director. While insider ownership can be a positive signal, this is a standard grant and doesn't necessarily indicate a significant shift in sentiment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Helen Collins acquired stock options. |
| 06/04/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.